Diamyd Medical Dirección

Dirección controles de criterios 3/4

El CEO de Diamyd Medical es Ulf Hannelius , nombrado en Apr 2016, tiene una permanencia de 8.58 años. compensación anual total es SEK3.01M, compuesta por 70.9% salario y 29.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.27% de las acciones de la empresa, por valor de SEK3.57M. La antigüedad media del equipo directivo y de la junta directiva es de 4.8 años y 20.8 años, respectivamente.

Información clave

Ulf Hannelius

Chief Executive Officer (CEO)

SEK 3.0m

Compensación total

Porcentaje del salario del CEO	70.9%
Permanencia del CEO	8.6yrs
Participación del CEO	0.3%
Permanencia media de la dirección	4.8yrs
Promedio de permanencia en la Junta Directiva	20.8yrs

Actualizaciones recientes de la dirección

Recent updates

We're Keeping An Eye On Diamyd Medical's (STO:DMYD B) Cash Burn Rate

Feb 02

We Think Diamyd Medical (STO:DMYD B) Needs To Drive Business Growth Carefully

Sep 22

What You Need To Know About Diamyd Medical AB (publ)'s (STO:DMYD B) Investor Composition

Jan 22

Here's Why Diamyd Medical's (STO:DMYD B) Statutory Earnings Are Arguably Too Conservative

Nov 30

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Ulf Hannelius en comparación con los beneficios de Diamyd Medical?
Fecha	Compensación total	Salario	Ingresos de la empresa
Aug 31 2024	n/a	n/a	-SEK 152m
May 31 2024	n/a	n/a	-SEK 140m
Feb 29 2024	n/a	n/a	-SEK 120m
Nov 30 2023	n/a	n/a	-SEK 116m
Aug 31 2023	SEK 3m	SEK 2m	-SEK 116m
May 31 2023	n/a	n/a	-SEK 119m
Feb 28 2023	n/a	n/a	-SEK 115m
Nov 30 2022	n/a	n/a	-SEK 99m
Aug 31 2022	SEK 3m	SEK 2m	-SEK 104m
May 31 2022	n/a	n/a	-SEK 91m
Feb 28 2022	n/a	n/a	-SEK 106m
Nov 30 2021	n/a	n/a	-SEK 83m
Aug 31 2021	SEK 3m	SEK 2m	SEK 60m
May 31 2021	n/a	n/a	SEK 74m
Feb 28 2021	n/a	n/a	SEK 99m
Nov 30 2020	n/a	n/a	SEK 121m
Aug 31 2020	SEK 3m	SEK 2m	SEK 10m
May 31 2020	n/a	n/a	SEK 13m
Feb 29 2020	n/a	n/a	SEK 13m
Nov 30 2019	n/a	n/a	-SEK 35m
Aug 31 2019	SEK 2m	SEK 1m	-SEK 37m
May 31 2019	n/a	n/a	-SEK 38m
Feb 28 2019	n/a	n/a	-SEK 43m
Nov 30 2018	n/a	n/a	-SEK 42m
Aug 31 2018	SEK 2m	SEK 1m	-SEK 44m

Compensación vs. Mercado: La compensación total ($USD273.52K) de Ulf está en línea con el promedio de empresas de tamaño similar en el mercado Swedish ($USD236.30K).

Compensación vs. Ingresos: La compensación de Ulf ha aumentado mientras la empresa no es rentable.

CEO

Ulf Hannelius (49 yo)

8.6yrs

Permanencia

SEK 3,006,000

Compensación

Mr. Ulf Hannelius, PhD, MBA, has been the Chief Executive Officer of Diamyd Medical AB (publ) since April 11, 2016 and serves as its President. Mr. Hannelius served as an Interim Chief Executive Officer at...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Ulf Hannelius	CEO & President	8.6yrs	SEK 3.01m	0.27% SEK 3.6m
Anna Styrud	Chief Financial Officer	no data	sin datos	0.14% SEK 1.8m
Martina Widman	Chief Operating Officer	2.4yrs	sin datos	0.012% SEK 157.5k
Anton Lindqvist	Chief Scientific Officer	7.2yrs	sin datos	sin datos
Maja Johansson	Chief Operating Officer of Manufacturing Site	1.8yrs	sin datos	0.0024% SEK 31.5k

4.8yrs

Permanencia media

49yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de DMYD B se considera experimentado (4.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Ake Lernmark	Member of the Scientific Advisory Board	28.8yrs	sin datos	sin datos
David Leslie	Member of the Scientific Advisory Board	25.8yrs	sin datos	sin datos
Daniel Kaufman	Member of the Scientific Advisory Board	28.8yrs	sin datos	sin datos
Anders Essen-Möller	Independent Chairman	28.8yrs	SEK 1.06m	3.13% SEK 41.1m
Mark Atkinson	Chairman of Scientific Advisory Board & Independent Director	27.8yrs	SEK 175.00k	0.016% SEK 211.0k
Karin Hehenberger	Independent Director	3.6yrs	SEK 125.00k	0.0096% SEK 126.0k
Erik Nerpin	Independent Vice Chairman	12.8yrs	SEK 230.00k	0.056% SEK 740.0k
Torbjörn Bäckström	Independent Director	7.8yrs	SEK 138.00k	0.00096% SEK 12.6k
Maria-Teresa Essen-Möller	Independent Director	15.8yrs	SEK 164.00k	1.31% SEK 17.2m
Karin Rosen	Independent Director	1.7yrs	SEK 28.00k	0.000010% SEK 131.2

20.8yrs

Permanencia media

65.5yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de DMYD B son experimentados ( 20.8 años antigüedad media).

Diamyd Medical Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Diamyd Medical AB (publ), Annual General Meeting, Dec 05, 2024

CEO & President exercised options to buy kr660k worth of stock.

Independent Chairman recently sold kr651k worth of stock

Diamyd Medical AB (Publ) Elects Karin Rosén as A New Member of the Board

Chairman recently bought kr72k worth of stock

Diamyd Medical AB (Publ) Announces Changes of the Board

Recent updates

Diamyd Medical AB (publ) Hits a Recruitment Milestone in DIAGNODE-3 Phase 3 Trial

Diamyd Medical AB (publ), Annual General Meeting, Dec 05, 2024

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Diamyd Medical AB (publ) to Report Q1, 2025 Results on Jan 29, 2025

CEO & President exercised options to buy kr660k worth of stock.

Diamyd Medical to Pursue Accelerated Approval Pathway for Type 1 Diabetes Precision Medicine

Diamyd Medical Announces Positive Interim Analysis Results for Phase 3 Trial in Type 1 Diabetes

New major risk - Share price stability

Third quarter 2024 earnings released

Diamyd Medical AB (publ) to Report Q4, 2024 Results on Nov 14, 2024

Diamyd Medical AB (publ) Updates on the Registrational Phase 3 Trial

Independent Chairman recently sold kr651k worth of stock

Recruitment Milestone Reaches in Diamyd® Phase 3 Trial

Second quarter 2024 earnings released

New minor risk - Share price stability

We're Keeping An Eye On Diamyd Medical's (STO:DMYD B) Cash Burn Rate

First quarter 2024 earnings released

In-Depth Analysis of Diamyd Medical AB (publ)'s Phase II Trial Further Supports Value of Presented Insulin Production

Diamyd Medical's Precision Medicine Patent for the Prevention and Treatment of Autoimmune Diabetes Granted in South Korea

Diamyd Medical AB (Publ) Elects Karin Rosén as A New Member of the Board

Diamyd Medical AB (publ) to Report Fiscal Year 2023 Results on Nov 30, 2023

Chairman recently bought kr72k worth of stock

Diamyd Medical AB (publ) has completed a Composite Units Offering in the amount of SEK 69.834709 million.

Diamyd Medical AB (Publ) Announces Follow-Up Study Recommends Diamyd to Offer Advantages in Delivering Type 1 Diabetes Onset

Diamyd Medical AB (publ) Announces Preliminary Results from Booster Trial with Diamyd Provide Additional Support for Intralymphatic Injection

Diamyd Medical AB (publ) to Report Q2, 2024 Results on Mar 27, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Diamyd Medical AB (Publ) Announces Changes of the Board

We Think Diamyd Medical (STO:DMYD B) Needs To Drive Business Growth Carefully

Diamyd Medical AB (Publ) Announces Registrational Phase III Trial in Type 1 Diabetes with Diamyd Expands to the US

New minor risk - Shareholder dilution

Price target decreased by 27% to kr19.00

Diamyd Medical AB (publ), Annual General Meeting, Nov 30, 2023

Third quarter 2023 earnings released

CEO & President recently bought kr88k worth of stock

Second quarter 2023 earnings released

Diamyd Medical Receives Patent Protection in the US and Japan for Gaba Formulation Remygen

First quarter 2023 earnings released: kr0.43 loss per share (vs kr0.52 loss in 1Q 2022)

Diamyd Medical Precision Medicine Patent for Prevention and Treatment of Autoimmune Diabetes to Be Granted in Eurasia

Diamyd Medical AB (Publ) Announces US Partial Clinical Hold on Diamyd® Phase III Trial Lifted by the FDA

Price target increased to kr19.50

Full year 2022 earnings released: kr1.35 loss per share (vs kr0.86 profit in FY 2021)

All Patients in DIAGNODE-B Have Received an Additional (Booster) Injection of Diamyd

Diamyd Medical AB (publ) to Report Q3, 2023 Results on Jun 28, 2023

Third quarter 2022 earnings released

Diamyd Medical AB (publ), Annual General Meeting, Dec 01, 2022

Diamyd Medical AB (publ) Announces First Patient Enrolled in its Phase III Trial DIAGNODE-3

Price target increased to kr19.50

Director recently sold kr1.0m worth of stock

Diamyd Medical AB Announces New Clinical Trial Will Evaluate an Additional Injection (Booster) with Diamyd

Second quarter 2022 earnings: Revenues miss analyst expectations

Clinical Trial in Type 1 Diabetes with Diamyd Medical's Remygen Is Fully Recruited

Diamyd Medical Proceeds with Initiation of Type 1 Diabetes Phase III Trial in Europe

First quarter 2022 earnings: Revenues miss analyst expectations

Diamyd Medical AB Patent for Intralymphatic Injection of GAD in Autoimmune Diabetes to Be Granted in China

Diamyd Medical Announces Australia Grants as the First Region Diamyd Medical A Broadening of A Patent for Intralymphatic Injection of Antigens in Autoimmune Diabetes

Director recently sold kr3.7m worth of stock

Diamyd Medical Pauses Start of Phase III Trial

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS kr0.86 (vs kr0.14 in FY 2020)

CEO & President recently bought kr112k worth of stock

CEO & President recently bought kr112k worth of stock

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS kr0.84 (vs kr0.14 in FY 2020)

Diamyd Medical AB Receives First Regulatory Approval to Start the Phase III Trial DIAGNODE-3 with the Diabetes Vaccine Diamyd®

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released

Diamyd Medical AB (Publ) Announces 24-Month Follow-Up of Phase IIb Diamyd® Clinical Trial Indicates Continued Similar Progression After 15 Months